AIMLogo.jpg
AIM ImmunoTech to Present at the MedInvest Biotech & Pharma Investor Conference
March 28, 2024 08:05 ET | AIM ImmunoTech Inc.
OCALA, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that Thomas K. Equels, MS JD, Chief Executive Officer of AIM...
AIMLogo.jpg
AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast
March 26, 2024 09:05 ET | AIM ImmunoTech Inc.
OCALA, Fla., March 26, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) announced today that management will host a conference call and webcast to discuss...
erasmus_mc_cover
AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research
March 25, 2024 09:05 ET | AIM ImmunoTech Inc.
OCALA, Fla., March 25, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM”) today announced the publication of new data analysis from a long-term Early Access Program (“EAP”)...
AIMLogo.jpg
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
March 22, 2024 08:55 ET | AIM ImmunoTech Inc.
OCALA, Fla., March 22, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced the next CEO Corner segment has been published on the Company’s...
Compass-logo-RGB-outlines.png
Compass Therapeutics Reports 2023 Financial Results and Provides Corporate Update
March 21, 2024 09:00 ET | Compass Therapeutics
Compass Therapeutics Reports 2023 Financial Results and Provides Corporate Update
Angelini Ventures Logo clear background.png
Angelini Ventures invests into extended €75.8 million ($82 million) Series C financing round for Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized cancer vaccines
March 21, 2024 03:00 ET | Angelini Ventures
Angelini Ventures joins syndicate of top-tier international healthcare investors in Nouscom’s Series C financing roundFinancing will enable Nouscom to continue advancing the clinical development of...
AIMLogo.jpg
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
March 20, 2024 09:25 ET | AIM ImmunoTech Inc.
OCALA, Fla., March 20, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced the next CEO Corner segment has been published on the Company’s...
AIMLogo.jpg
AIM ImmunoTech to Participate in the Virtual Investor Lunch Break: The AIM Opportunity
March 15, 2024 08:45 ET | AIM ImmunoTech Inc.
OCALA, Fla., March 15, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced that it will present at the Virtual Investor Lunch Break: The AIM...
AIM CEO Corner
AIM ImmunoTech Announces Launch of CEO Corner Platform
March 07, 2024 08:45 ET | AIM ImmunoTech Inc.
CEO Corner segments to provide added perspective to press releases, corporate developments and pipeline progress Provides interested parties the ability to ask questions and submit topics for future...
arvinas_logoART_lg.jpg
Arvinas to Participate in Upcoming Investor Conferences
March 04, 2024 07:00 ET | Arvinas Inc.
NEW HAVEN, Conn., March 04, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...